IRMD Company Profile and Key Details

IRMD has shown sold momentum, gaining 5.19% over the past week and 40.97% over the past quarter, though year-to-date performance is up 5.86%. Short-term trend indicators are bearishly aligned (SMA20 -5.15%, SMA50 -2.66%, SMA200 28.13%). The stock’s 14-day RSI is 39.42 (weak momentum), while the ATR of 2.9 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -9.9% below its high and over 100.16% above its low. Average 10-day trading volume of 69.58 thousand shares is in line with the 3-month average of 74.17 thousand, indicating normal recent market interest.

IRadimed Corporation generated EPS of $1.65 over the past year. Five-year average earnings growth is 13.91%. Wall Street analysts project EPS growth of 10.67% annually over the next five years. The latest quarter delivered EPS of $0.47. The next quarter is forecast at $0.48. Next year's EPS is expected at $15.28. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 1 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $72.00 to $72.00. The high target offers -23.84% upside. The low target suggests -23.84% downside. The mean target is $72.00. This offers -23.84% upside. IRadimed Corporation earnings surprise history is a mixed track record. The quarter that ended November 03, 2025, missed forecasts by 9.3%. The prior quarter beat by 8.89%. Over the last six quarters, Apple has recorded several small beats. These include 6.72% in August 01, 2024.

IRadimed Corporation has 12.72 million shares outstanding. The public float is 7.17 million shares, elevated short interest at 2.64% of float. This equals 212.13 thousand shares. The short ratio is 4.48 days. Institutional investors hold 93.84% of the float. Insiders own 36.81%. Susi Roger E. holds 2.26 million shares, HAWKINS JAMES B has 28.74 thousand shares and ALLEN MONTY K has 19.90 thousand shares. Over the past six months, insider transactions show net selling. They sold 38.22 thousand shares across 24 transactions.

IRadimed Corporation (NASDAQ:IRMD) closed at $94.54 USD, gaining $0.69 (0.74%) from the previous close of $93.85. The stock is currently mid-range between its 52-week high and low $47.48 and $104.93. With a market capitalization of about $1.20 billion, IRadimed Corporation is classified as a small-cap and shows market-like volatility (beta ~1.14). Key stats such as the average daily volume over the past year has been around 76.06 thousand shares, in line with its 52-week average. Headquartered in Winter Springs, FL, IRadimed Corporation operates in the Healthcare sector and the Medical - Devices industry. Led by CEO Roger E. Susi, the company employs approximately 160 people and listed since July 16, 2014. IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices, and related accessories and services in the United States and internationally.

IRadimed Corporation last paid a dividend of 1.18 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $49.49. This means the shares are trading above this model’s fair value.

IRadimed Corporation trades at a P/E ratio of 56.83, slightly above the S&P 500 average, with a price-to-sales ratio of 14.95 and a price-to-book ratio of 12.24 reflecting a rich premium to book value. The P/FCF stands at 84.21, also above market averages. Compared to sector medians, IRadimed Corporation P/S is trading rich, and the P/B is far higher than peers, underscoring the brand and earnings power premium investors assign to the stock.

Our AI price prediction model suggests that IRadimed Corporation stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -5.09%, with price expected at $89.73 by February 19, 2026, within a range of $87.98 to $91.40 3-Month Outlook: Projected fall of -52.3%, reaching $45.10 by May 05, 2026, with a range of $42.10 to $47.46. 1-Year Outlook: Projected gain of 14.03%, with price at $107.80 by February 05, 2027, within a range of $104.72 to $111.19.

IRadimed Corporation (NASDAQ:IRMD) shares are flat 5.86% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows IRadimed Corporation trading at a premium to the broader market with a P/E of 56.83. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $36.62, suggesting -61.27% downside. Our AI forecast model points to short-term weakness (-5.09% over two weeks), a medium-term fall (-52.3% over three months), and a longer-term gain (14.03% over one year), with expected trading ranges indicating moderate volatility.